From whispered remedies to clinical reality

Richard Moore
Jan 23
12 min read

Mushrooms have travelled from folklore to lab benches. Not all of them made it with evidence intact

For thousands of years, cultures across East Asia and beyond treated certain mushrooms as more than food, using them as tonics for stamina, sleep and resilience, long before anyone could measure inflammation, neurotransmitters, or markers of brain injury in a blood sample (Venturella et al., 2021). The modern story is not that ancient tradition was “right about everything.” It is that today’s tools and trial designs let us separate plausible signals from compelling folklore, and that matters most in neurodegenerative disease and acquired brain injury, where hope is essential but overpromising can be costly (Cha et al., 2024).

This blog focuses on the mushrooms with the most brain-relevant human evidence and clearly flags where evidence is thin, indirect, or not yet specific to diagnosed disease (Cha et al., 2024). You will see Lion’s Mane and Tremella featured more heavily because they have published randomised, placebo-controlled human trials that measured cognitive outcomes (Mori et al., 2009; Ban et al., 2018; Bizjak et al., 2024). You will see psilocybin handled separately, because it belongs to a different regulatory and clinical category than over-the-counter mushroom extracts, and its strongest neurology data to date is focused on Parkinson’s-related mood symptoms rather than slowing disease progression (Bradley et al., 2025).

The hope trap (and how to avoid it)

“Brain health” is not the same promise as “slowing disease”, and the difference protects you.

When people say “medicinal mushrooms for dementia, Parkinson’s, stroke, ALS/MND,” they often blend three very different goals into one headline: helping day-to-day symptoms (like mood or subjective memory), shifting intermediate biology (like inflammatory markers or neurotrophic signals), and slowing the underlying disease itself (Cha et al., 2024). In today’s human literature, the strongest signals tend to sit in the symptom-adjacent zone (mood, subjective cognition, processing speed), while the weakest evidence is for hard endpoints such as disability progression, institutionalisation, or survival (Cha et al., 2024).

A useful analogy is a weather forecast versus climate. A supplement might change “today’s conditions” for some people (how they feel, sleep, concentrate), while the “climate” of a disease (the long-term trajectory) remains unchanged. Trials that prove climate change in neurodegeneration are difficult, expensive, and rare. That does not make symptom-level signals meaningless. It simply means we should keep claims proportionate to the rung of the ladder the evidence actually occupies (Cha et al., 2024).

The Identity problem: when ‘mushroom’ does not mean ‘mushroom’

Two products can share a name and still behave like entirely different interventions.

Yes, the form matters, because “a mushroom” is not a single ingredient. Across studies, products vary by species, whether the intervention used fruiting body or mycelium, the dose, extraction method (for example hot-water extracts versus other processes), and whether any bioactive fraction is standardised (Cha et al., 2024; Venturella et al., 2021). This is one reason findings can be hard to compare between trials and why one person’s experience with a brand does not automatically translate to another (Cha et al., 2024).

Think of it like coffee. “Coffee” can mean a weak instant drink or a concentrated espresso, and your response will differ. Mushroom interventions have the same identity problem: a capsule may be powdered whole mushroom, a beta-glucan–enriched extract, or a multi-step extract targeting different compounds. Without clarity on what was used, you cannot reliably map marketing claims back to research (Cha et al., 2024).

Across the cognition-focused trials discussed below, tolerability is generally reported as acceptable in the studied groups (Mori et al., 2009; Ban et al., 2018; Qin et al., 2019). However, “safe in a small trial” is not the same as “appropriate for everyone,” particularly when immunosuppression, anticoagulants, complex medication regimens, or allergy risk are present (Cha et al., 2024).

Lion’s Mane: the one that actually faced a test

It is not a miracle, but it has done something rare: cognition was measured under blinded conditions.

Lion’s Mane stands out because it has been studied in human trials that measured cognition directly, rather than simply inferring brain benefit from laboratory markers (Cha et al., 2024). In a double-blind, placebo-controlled trial in older adults with mild cognitive impairment (MCI), Hericium erinaceus supplementation improved cognitive scores during the intake period, with scores decreasing after discontinuation (Mori et al., 2009). That pattern is consistent with an effect that may require ongoing use to maintain, though it does not prove any change in long-term disease progression (Mori et al., 2009).

More recently, an 8-week randomised, double-blind, placebo-controlled pilot study using an erinacine A-enriched Hericium supplement reported improvements in measures of cognitive processing speed, alongside changes in circulating brain-derived neurotrophic factor (BDNF) and signals related to gut microbiota diversity (Bizjak et al., 2024). The critical interpretation is not that Lion’s Mane is a proven treatment for dementia or Parkinson’s. It is that it has crossed a key threshold: cognition has shifted under blinded conditions in humans, which is a higher rung of evidence than “promising in animals” (Cha et al., 2024; Mori et al., 2009; Bizjak et al., 2024).

For disease-specific claims, restraint matters. In ALS/MND, ALSUntangled’s conclusion is clear: there is currently not enough evidence to support Lion’s Mane for treating ALS, and ALS-specific research is missing (Muhanna et al., 2023; ALSUntangled, n.d.).

Tremella: the quiet one with real human data

Not famous, not flashy, but it has been studied in people, with cognition on the scoreboard.

Tremella has something that should carry more weight than popularity: a published randomised, double-blind, placebo-controlled human trial in individuals with subjective cognitive impairment (SCI) (Ban et al., 2018). In that 8-week trial, Tremella fuciformis at 600 mg/day or 1200 mg/day was associated with improvements in subjective memory complaint scores and performance on tests of short-term memory and executive functions compared with placebo, with exploratory brain imaging analyses also reported (Ban et al., 2018).

A note on terminology: studies may include brain imaging outcomes such as functional magnetic resonance imaging (fMRI) or structural MRI analyses, but the presence of imaging does not automatically mean a treatment is “changing the disease.” Imaging can help researchers explore mechanisms or detect subtle patterns, yet it still needs to be paired with meaningful clinical outcomes to justify strong claims (Ban et al., 2018).

The best reading of Tremella’s evidence is “signal worth following.” SCI is not the same as a diagnosed neurodegenerative disease, and an 8-week window cannot answer whether progression changes (Ban et al., 2018).

Reishi: the trial that keeps marketing honest

The Alzheimer’s pilot study exists, and it does not say what the internet wants it to say.

Reishi has a large traditional footprint and extensive preclinical literature, but brain-relevant human intervention evidence is narrower than many marketing narratives imply (Venturella et al., 2021; Cha et al., 2024). One of the most directly relevant clinical datasets is a pilot randomised trial in people with Alzheimer’s disease testing spore powder of Ganoderma lucidum over 6 weeks, where outcomes such as cognition and neuropsychiatric measures did not show significant benefit versus placebo, while adverse events were generally mild (Qin et al., 2019).

Null or negative results are not failures. They are essential guardrails. In neurodegeneration, short trials and small samples can miss subtle effects, but they also protect families from confident claims that run ahead of evidence (Qin et al., 2019).

Shiitake and Maitake: the ‘food-first’ plot twist

Their best brain story may not be a supplement at all. It may be what ends up on your plate.

Shiitake (Lentinula edodes) and maitake (Grifola frondosa) are often grouped into “medicinal mushrooms,” but their strongest brain-adjacent case in humans may be dietary and epidemiological rather than disease-specific supplement trials (Cha et al., 2024). Observational studies have reported associations between higher mushroom consumption and lower odds of mild cognitive impairment (Feng et al., 2019). A prospective study in Japan reported an association between mushroom intake and lower risk of incident disabling dementia in women, with no clear association observed in men (Aoki et al., 2024).

These designs cannot prove causation, but they support a grounded message: culinary mushrooms may contribute to a broader dietary pattern linked with cognitive resilience (Feng et al., 2019; Aoki et al., 2024). One mechanistic bridge attracting serious interest is ergothioneine, an antioxidant concentrated in mushrooms (Cha et al., 2024). In a prospective study (the Hisayama Study), higher serum ergothioneine levels were associated with a lower risk of developing dementia outcomes (Meng et al., 2025). In a placebo-controlled pilot trial in people with mild cognitive impairment, ergothioneine intake was reported as safe and associated with improved learning performance and stabilisation of plasma (NfL), a biomarker often discussed in relation to neuroaxonal injury (Yau et al., 2024).

This is where “food as background therapy” becomes a practical concept. You do not need a miracle claim to justify mushrooms on the plate. You need a plausible, low-risk, repeatable habit that fits daily life and aligns with observational signals and emerging mechanistic targets (Cha et al., 2024; Feng et al., 2019).

Turkey Tail, Chaga, Cordyceps: the ‘promising, not proven’ chapter

These mushrooms have biology worth studying, but brain-specific human outcomes are still thin.

Turkey Tail (Trametes versicolor) is best known for immune-focused research and clinical use in non-neurological contexts, which is part of why it appears less often in cognition or neurodegeneration intervention trials (Venturella et al., 2021; Cha et al., 2024). Chaga (Inonotus obliquus) has substantial preclinical discussion, but robust human trials directly testing cognition, stroke recovery, or neurodegenerative outcomes are not yet a defining feature of the evidence base families can rely on (Cha et al., 2024).

Cordyceps is frequently discussed in relation to energy metabolism and ischaemia-related pathways, and a comprehensive review summarises potential relevance to ischaemic cardio-cerebrovascular injury (Li et al., 2024). However, for stroke and traumatic brain injury, the most meaningful question is not only whether oxidative stress pathways can be influenced in theory, but whether function improves in practice. The human recovery-trial evidence remains the limiting step for confident clinical claims (Li et al., 2024; Cha et al., 2024).

Psilocybin: not a supplement story, a supervised therapy story

Early Parkinson’s data centres on mood and wellbeing, not a cure, and not self-experimentation.

Psilocybin is not an over-the-counter supplement story. It is a regulated psychoactive compound studied in controlled clinical settings, typically paired with psychological support (Bradley et al., 2025). In the UK, “magic mushrooms” are listed as Class A drugs in official guidance, and research involving such substances sits within strict legal and ethical frameworks (UK Government, n.d.; UK Health Research Authority, 2021).

The most directly relevant neurology study to date is an open-label pilot trial of psilocybin therapy in people with Parkinson’s disease with depression and/or anxiety, reporting feasibility and a tolerable safety profile in a small sample, with outcomes centred on mood and wellbeing rather than disease modification (Bradley et al., 2025). This is meaningful because mood dysfunction can be a major driver of suffering and reduced quality of life in Parkinson’s, and improving that domain can be clinically significant even without changing progression (Bradley et al., 2025).

For traumatic brain injury, a 2025 narrative review concludes that mechanistic rationales exist and adjacent psychiatric evidence is encouraging, but it also makes clear that clinical trials in traumatic brain injury (TBI) remain a gap rather than an established therapy pathway (Palmer et al., 2025).

Where the evidence lands: a map, not a sales pitch

What we know, what we suspect, and what we simply do not have yet for ALS/MND, dementia, Parkinson’s, stroke, and brain injury.

For dementia and Alzheimer’s, the clearest cognition-focused human trial signals among the mushrooms discussed are Lion’s Mane in mild cognitive impairment and Tremella in subjective cognitive impairment, both suggesting potential symptomatic cognitive benefits in defined contexts rather than proof of disease modification (Mori et al., 2009; Ban et al., 2018; Bizjak et al., 2024). Reishi has been tested in an Alzheimer’s pilot trial with no significant cognitive benefit over 6 weeks, which should temper marketing claims (Qin et al., 2019). Population studies link higher mushroom intake with lower risk signals in some cohorts, but these do not prove mushrooms caused the benefit (Feng et al., 2019; Aoki et al., 2024).

For Parkinson’s disease, the most distinctive mushroom-adjacent human evidence in the material above is psilocybin therapy for mood dysfunction in a pilot trial, which should be framed as early-stage research into a high-burden symptom domain under medical supervision, not a strategy for motor improvement or slowed progression (Bradley et al., 2025; UK Health Research Authority, 2021).

For stroke and brain injury, the sober summary is that robust, brain-function-focused human trials for most mushrooms remain limited, and the field is still bridging from mechanistic plausibility to functional recovery outcomes (Cha et al., 2024; Li et al., 2024). For psilocybin in TBI, the current literature is best described as rationale and review-level discussion rather than proven clinical benefit in rehabilitation. (Palmer et al., 2025)

For ALS/MND, the responsible conclusion is that supportive human evidence for medicinal mushrooms as ALS treatments is largely absent, and ALSUntangled’s review of Lion’s Mane explicitly reflects this gap (Muhanna et al., 2023; ALSUntangled, n.d.).

The practical takeaway: a decision framework for real life

Not a shopping list. A way to choose calmly when the stakes feel personal.

First, if you want the lowest-friction, most evidence-aligned starting point, prioritise culinary mushrooms as a repeatable food habit rather than chasing high-dose supplement stacks. Observational studies linking mushroom intake with lower odds of cognitive impairment support this as a pragmatic dietary inclusion, even though causation is not proven (Feng et al., 2019; Aoki et al., 2024).

Second, if you are considering supplements, anchor your choices to the interventions with the clearest human cognition endpoints. On current evidence, Lion’s Mane and Tremella are more defensible “brain-focused” candidates than species where brain outcomes remain largely preclinical, but expectations should stay in the lane of symptom support rather than cure or slowed disease progression (Mori et al., 2009; Ban et al., 2018; Bizjak et al., 2024; Cha et al., 2024).

Third, treat product identity as part of the intervention. Look for clear species identification, whether the product uses fruiting body versus mycelium, dose transparency, and standardisation or batch testing where available. This does not guarantee efficacy, but it reduces the risk of buying a label rather than something comparable to what a trial tested (Cha et al., 2024; Venturella et al., 2021).

Fourth, protect the fundamentals. Neurodegenerative disease and brain injury outcomes are heavily influenced by basics that no supplement can replace, including adequate nutrition, sleep, medication adherence, and rehabilitation inputs where relevant. Mushrooms, at best, are adjuncts (Cha et al., 2024).

Finally, keep psilocybin in the correct box. In the UK context, it should be understood as a legally restricted, medically supervised research pathway with early evidence for mood-related outcomes in Parkinson’s and theoretical interest in TBI, not an at-home supplement strategy or a disease-modifying claim (UK Government, n.d.; UK Health Research Authority, 2021; Bradley et al., 2025; Palmer et al., 2025).

Ready to make sense of the noise?

If you are living with a neurodegenerative condition (or supporting someone who is), it can be difficult to separate hopeful ideas from evidence you can actually trust. You Nutrition Clinic offers personalised, practitioner-led nutrition and lifestyle support designed to work alongside your medical care, with a focus on realistic routines, symptom-aware strategies, and clear interpretation of what research does and does not show.

If you would like structured guidance tailored to your diagnosis, medications, appetite, weight changes, swallowing considerations, fatigue, and daily capacity, you can book an initial call with You Nutrition Clinic to explore whether support is a good fit for you.

Book a free initial call: admin@younutritionclinic.com

🧩 Connect with us

For research updates, practical tips, and ongoing inspiration, follow us on Instagram:

👉 @nutritionandthebrain

Stay curious. Stay hopeful. Support your brain. 🧠

References

ALSUntangled. (n.d.). Lion’s Mane. ALSUntangled®.

Aoki, S., Yamagishi, K., et al. (2024). Mushroom intake and risk of incident disabling dementia: The Circulatory Risk in Communities Study (CIRCS). British Journal of Nutrition. https://doi.org/10.1017/S000711452400014X

Ban, S., Lee, S. L., Jeong, H. S., Lim, S. M., Park, S., Hong, Y. S., & Kim, J. E. (2018). Efficacy and safety of Tremella fuciformis in individuals with subjective cognitive impairment: A randomized controlled trial. Journal of Medicinal Food, 21(4), 400–407. https://doi.org/10.1089/jmf.2017.4063

Bizjak, M. Č., Jenko Pražnikar, Z., Kenig, S., Hladnik, M., Bandelj, D., Gregori, A., & Kranjc, K. (2024). Effect of erinacine A-enriched Hericium erinaceus supplementation on cognition: A randomized, double-blind, placebo-controlled pilot study. Journal of Functional Foods, 115, 106120. https://doi.org/10.1016/j.jff.2024.106120

Bradley, E. R., et al. (2025). Psilocybin therapy for mood dysfunction in Parkinson’s disease: An open-label pilot trial. Neuropsychopharmacology, 50(8), 1200–1209. https://doi.org/10.1038/s41386-025-02097-0

Cha, S., Bell, L., Shukitt-Hale, B., & Williams, C. M. (2024). A review of the effects of mushrooms on mood and neurocognitive health across the lifespan. Neuroscience & Biobehavioral Reviews, 158, 105548. https://doi.org/10.1016/j.neubiorev.2024.105548

Feng, L., Cheah, I. K. M., Ng, M. M. X., Li, J., Chan, S. M., Lim, S. L., Mahendran, R., & Kua, E. H. (2019). The association between mushroom consumption and mild cognitive impairment: A community-based cross-sectional study in Singapore. Journal of Alzheimer’s Disease, 68(1). https://doi.org/10.3233/JAD-180959

Li, Y., et al. (2024). Cordyceps: Alleviating ischemic cardiovascular and cerebrovascular injury. Journal of Ethnopharmacology, 332, 118321. https://doi.org/10.1016/j.jep.2024.118321

Meng, X., Ohara, T., Ninomiya, T., et al. (2025). Serum ergothioneine and risk of dementia in a general older Japanese population: The Hisayama Study. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13893

Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: A double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372. https://doi.org/10.1002/ptr.2634

Muhanna, M., Lund, I., Bromberg, M., et al. (2023). ALSUntangled #73: Lion’s Mane. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25(3–4), 420–423. https://doi.org/10.1080/21678421.2023.2296557

Palmer, C., Ferber, A. T., & Greenwald, B. D. (2025). The potential role of psilocybin in traumatic brain injury recovery: A narrative review. Brain Sciences, 15(6), 572. https://doi.org/10.3390/brainsci15060572

Qin, L. H., Wang, G., Wang, L., & Wang, C. (2019). Spore powder of Ganoderma lucidum for the treatment of Alzheimer’s disease: A pilot study. Medicine, 98(5), e14358. https://doi.org/10.1097/MD.0000000000014358

UK Government. (n.d.). Drugs penalties. GOV.UK.

UK Health Research Authority. (2021, May 19). Researching magic mushrooms: When ethics and law collide.

Venturella, G., Ferraro, V., Cirlincione, F., & Gargano, M. L. (2021). Medicinal mushrooms: Bioactive compounds, use, and clinical trials. International Journal of Molecular Sciences, 22(2), 634. https://doi.org/10.3390/ijms22020634

Yau, Y. F., et al. (2024). Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. Journal of Alzheimer’s Disease, 102(3), 841–854. https://doi.org/10.1177/13872877241291253